Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects

The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of the CYP3A4 Probe Midazolam.

Inclusion Criteria:

• Healthy male and female subjects aged 18 to 49 years, with BMI of 18-32 kg/m²
• Women who are not of childbearing potential

Exclusion Criteria:

• Women of childbearing potential
• Women who are pregnant, breastfeeding, or unwilling or unable to use an acceptable method of birth control.
• Gastrointestinal disease that may impact the absorption of study drug
• History of any chronic respiratory disease (asthma, COPD)